These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7564933)

  • 21. Revising a priority list based on cost-effectiveness: the role of the prominence effect and distorted utility judgments.
    Baron J; Ubel PA
    Med Decis Making; 2001; 21(4):278-87. PubMed ID: 11475384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The trade-off between severity of illness and treatment effect in cost-value analysis of health care.
    Nord E
    Health Policy; 1993 Aug; 24(3):227-38. PubMed ID: 10128127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new explanation for the difference between time trade-off utilities and standard gamble utilities.
    Bleichrodt H
    Health Econ; 2002 Jul; 11(5):447-56. PubMed ID: 12112493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The origin of informed consent].
    Mallardi V
    Acta Otorhinolaryngol Ital; 2005 Oct; 25(5):312-27. PubMed ID: 16602332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preference-based measures in economic evaluation in health care.
    Neumann PJ; Goldie SJ; Weinstein MC
    Annu Rev Public Health; 2000; 21():587-611. PubMed ID: 10884966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A person trade-off study to estimate age-related weights for health gains in economic evaluation.
    Petrou S; Kandala NB; Robinson A; Baker R
    Pharmacoeconomics; 2013 Oct; 31(10):893-907. PubMed ID: 23990389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using the person trade-off approach to examine differences between individual and social values.
    Dolan P; Green C
    Health Econ; 1998 Jun; 7(4):307-12. PubMed ID: 9683091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An instrument for measuring the social willingness to pay for health state improvement.
    Richardson J; Iezzi A; Sinha K; Khan MA; Mckie J
    Health Econ; 2014 Jul; 23(7):792-805. PubMed ID: 23824989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Societal value, the person trade-off, and the dilemma of whose values to measure for cost-effectiveness analysis.
    Ubel PA; Richardson J; Menzel P
    Health Econ; 2000 Mar; 9(2):127-36. PubMed ID: 10721014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distributive justice and rationing in the NHS: framing effects in press coverage of a controversial decision.
    Burgoyne CB
    J Community Appl Soc Psychol; 1997 Apr; 7(2):119-36. PubMed ID: 11656682
    [No Abstract]   [Full Text] [Related]  

  • 31. In the best interest of the patient. Applying this standard to healthcare decision making must be done in a community context.
    Trau JM; McCartney JJ
    Health Prog; 1993 Apr; 74(3):50-6. PubMed ID: 10124676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A note on cost-value analysis.
    Østerdal LP
    Health Econ; 2003 Mar; 12(3):247-50; discussion 251-3. PubMed ID: 12605468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Social valuation of EQ-5D health states: the Chilean case.
    Zarate V; Kind P; Valenzuela P; Vignau A; Olivares-Tirado P; Munoz A
    Value Health; 2011 Dec; 14(8):1135-41. PubMed ID: 22152184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality-adjusted life years, utility theory, and healthy-years equivalents.
    Mehrez A; Gafni A
    Med Decis Making; 1989; 9(2):142-9. PubMed ID: 2501627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health state utility anchors: being clear on what "1" means.
    O'Brien BJ
    Med Decis Making; 1997; 17(3):352-3. PubMed ID: 9219197
    [No Abstract]   [Full Text] [Related]  

  • 36. Longevity bias in cost-effectiveness analysis.
    Liu L; Rettenmaier AJ; Saving TR
    Health Econ; 2008 Apr; 17(4):523-34. PubMed ID: 17990284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assigning values to intermediate health states for cost-utility analysis: theory and practice.
    Cohen BJ
    Med Decis Making; 1996; 16(4):376-85. PubMed ID: 8912299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Which quality of life measures fit your relative effectiveness assessment?
    Cleemput I; Neyt M
    Int J Technol Assess Health Care; 2015 Jan; 31(3):147-53. PubMed ID: 26062796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges to time trade-off utility assessment methods: when should you consider alternative approaches?
    Boye KS; Matza LS; Feeny DH; Johnston JA; Bowman L; Jordan JB
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):437-50. PubMed ID: 24832003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elicitation of informed general population health state utility values: a review of the literature.
    McTaggart-Cowan H
    Value Health; 2011 Dec; 14(8):1153-7. PubMed ID: 22152187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.